Traumatic Splenic Injury and Management (SPLENIQ Study)

Summary

OBJECTIVE:

To determine the quality of life (QOL) and clinical outcome after conservative therapy, embolization (proximal versus distal) or surgery in patients with traumatic splenic injury. Secondary aims: (I) to examine therapy-related complications, (II) to establish the necessity of additional therapies, (III) the assessment of splenic function related to splenic morphology (MR imaging) after embolization and (IV) to find the prognostic factors for failure of non-operative management (NOM) in patients with splenic injuries. Finally, with the acquired data from this study a patient-oriented protocol will be provided for the management of traumatic splenic injury.

HYPOTHESIS:

The investigators expect that NOM is superior to surgery with regard to QOL, clinical outcome and splenic function. Embolization will need more additional therapies. Splenic morphology is related to splenic immune function. Expected prognostic factors are age above 40, ISS \>25 and a splenic injury grade of 3 or higher.

STUDY DESIGN:

A combination of a retrospective and a prospective multicentre cohort study. This protocol involves the prospective part of the study.

STUDY POPULATION/DATASET:

Patients who enter the participating hospitals between March 2017 and December 2018 with splenic injury will be asked to participate. The follow-up period will be one year with regard to QOL, clinical symptoms and imaging.

INTERVENTION:

All patients will complete a number of questionnaires at different time points. The patients who were treated with splenic artery embolization (SAE) will undergo an MRI one month and one year after treatment.

OUTCOME MEASURES:

Primary outcome is QOL. Secondary outcomes are clinical symptoms and imaging.

SAMPLE SIZE:

Approximately 100 patients will be included per year during the inclusion phase.

DATA ANALYSIS:

With regard to the prospective data linear modelling will be performed.

COLLABORATION/CONNECTION:

Tilburg University, Erasmus Medical Center Rotterdam, Maasstad Hospital Rotterdam, Albert Schweitzer Hospital Dordrecht, Amphia hospital Breda, Leiden University Medical Center, VU University Medical Center Amsterdam, Medical Spectrum Twente, Radboud University Nijmegen, Isala Zwolle.

TIME SCHEDULE:

Year 1: literature search and conducting the retrospective study and analyses. Years 1-3: inclusion prospective study and follow-up of patients. Year 4: finishing follow-up data collection and analysing.

Conditions

• Quality of Life
• Spleen Injury
• Trauma
• Splenic Artery Embolization

Interventions

OTHER

Questionnaires

All patients will complete a number of questionnaires at different time points. * SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ * 1 week, 1 month, 3, 6 and 12 months after treatment

DIAGNOSTIC_TEST

MRI abdomen

Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.

Sponsors & Collaborators

• Erasmus Medical Center

  collaborator OTHER

• Maasstad Hospital

  collaborator OTHER

• Albert Schweitzer Hospital

  collaborator OTHER

• Amphia Hospital

  collaborator OTHER

• Tilburg University

  collaborator OTHER

• Leiden University Medical Center

  collaborator OTHER

• Amsterdam UMC, location VUmc

  collaborator OTHER

• Medisch Spectrum Twente

  collaborator OTHER

• Radboud University Medical Center

  collaborator OTHER

• Isala

  collaborator OTHER

• Elisabeth-TweeSteden Ziekenhuis

  lead OTHER

Principal Investigators

• Jolanda de Vries, Prof. dr. · Project leader (ETZ Tilburg, Tilburg University)

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-03-01

Primary Completion

2020-12-31

Completion

2020-12-31

Countries

• Netherlands

Study Locations